Supplements

Food Insecurity and the Dangers of Infant Formula Dilution

Course grounded in behavior change science combines hands-on CBT techniques with sustained support to enhance pediatric mental health care.

January 30th 2023

Weekly review: New peanut patch data, norovirus outbreaks, and more

Demystifying Infant Formula

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

October 11th 2022

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

January 10th 2025

New data: Viaskin Peanut patch improves treatment benefit through 36 months

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

January 9th 2025

The Reach Institute addresses rising cases of youth depression with new program for primary care providers

In an open-label extension of the EPITOPE phase 3 trial, the Viaskin Peanut patch had continued improvement in toddlers aged 1-3 years through 36 months.

Related Content

The REACH Institute

Food Insecurity and the Dangers of Infant Formula Dilution

Course grounded in behavior change science combines hands-on CBT techniques with sustained support to enhance pediatric mental health care.

January 30th 2023

Weekly review: New peanut patch data, norovirus outbreaks, and more

Demystifying Infant Formula

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

October 11th 2022

Data: 80% of INZ-701-treated infants with ENPP1 Deficiency survived past first year

January 10th 2025

New data: Viaskin Peanut patch improves treatment benefit through 36 months

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

January 9th 2025